



# **ART-treated adults with diagnosed atherosclerosis are characterized by a particular expression of Regulatory T-cells (Tregs)**

Celine Rothan<sup>1</sup>, Alexis Yero<sup>1</sup>, Tao Shi<sup>1</sup>, Omar Farnos<sup>1</sup>, Mohamed El-Far<sup>2</sup>, Petronela Ancuta<sup>2</sup>, Carl Chartrand-Lefebvre<sup>2</sup>, Cecilia T Costiniuk<sup>3</sup>, Christos Tsoukas<sup>4</sup>, Cecile Tremblay<sup>2</sup>, Madeleine Durand<sup>2</sup>, Mohammad-Ali Jenabian<sup>1</sup>

<sup>1</sup> Department of Biological Sciences, Université du Québec à Montréal (UQAM), Montreal, QC.

<sup>2</sup> Centre de Recherche du CHUM and Université de Montréal, Montreal, QC.

<sup>3</sup> Chronic Viral Illness Service and Research Institute of McGill University Health Centre, Montreal, QC.

<sup>4</sup> Division of Clinical Immunology and Allergy and Research Institute of McGill University Health Centre, Montreal, QC.

## Chronic HIV infection: accelerated aging and increased Treg frequencies

I. Generalized **immune-activation** and persistent **inflammation**, which promote:

- a) Release of **pro-inflammatory cytokines** and **endothelial adhesion molecules**. (Zicari, *et al.* 2019. Viruses)
- b) Recruitment of leukocytes
- c) Oxidative stress (Aukrust, *et al.* 2005. Blood)

result in accelerated aging and cardiovascular diseases:

- Immuno-senescence and exhaustion
- Organ damage and dysfunction

II. **Increased in Tregs frequencies** (Jenabian *et al.* 2011. PLoS Pathogens)

- a) Inhibition of specific anti-HIV response
- b) Promote tissue fibrosis (Sanchez *et al.* 2015. JID)
- c) Contribute to viral persistence (Yan-Mei *et al.* 2015. Int J Inf Diseases)

III. **Increased CD39/Adenosine purinergic pathway** (Jenabian et al., 2013, PLoS Path)

IV. **Decrease in Th17 cells counts**. (Ancuta *et al.* 2010. Curr Opin HIV AIDS)

Contribute to microbial translocation in the gut and further generalized immuno-activation.

## Atherosclerosis:

I. Inflammatory disease

II. Decrease levels of atheroprotective Tregs (Winkels, H. *et al.* 2017. Eur Heart J)

a) Tregs also promote atheroma plaque stability.

III. Decrease levels of atheroprotective CD39/CD73. (Huttinger, *et al.* (2012). Am J Pathol; Koszalka, *et al.* 2004. Circ Res)


IV. Increase levels of pro-atherogenic Th17 cells. (Bixler, *et al.* 2013. Clin Dev Immunol)

## METHODS:


- n= 142, including ART-treated HIV<sup>+</sup> adults with (n=43) or without atherosclerosis (n=41) and HIV<sup>-</sup> individuals with (n=30) or without atherosclerosis (n=28).
- Atherosclerosis was determined by the presence of atherosclerotic features by computed tomography angiography of the coronary arteries.
- *Ex vivo* analysis of the frequency of Treg subsets and T-helper (Th) cells, as well as T-cell immune activation were assessed by flow cytometry.

**Despite increased proportion of Tregs, increased expression of CD39 and decreased number of Th17 in HIV infection, the incidence of atherosclerosis is increased in HIV-infected patients??**

HIV-infected individuals with atherosclerosis have higher levels of circulating total Tregs, while Tregs in HIV+CVD+ group are less differentiated




Increased generation of thymic Tregs in HIV+CVD+ individuals




- **CD31:** marker of recently Treg migrated from the thymus
- **Helios:** marker of thymic Treg

## HIV+CVD+ individuals have lower frequencies of circulating atheroprotective CD39/CD73-expressing Tregs




Tregs in HIV+CVD+ individuals are characterized by low levels of CXCR3 and CCR4 expression suggesting an impairment in Treg maintenance and migration to the atheroma plaque



- CXCR3<sup>+</sup> Tregs are protective in acute inflammation. (Fernandes, J. *et al.* (2004). Cytok)
- CXCR3 guide T-cells migration to atheroma plaque. (Clement, M. *et al.* (2015). J Autoimmun)
- CCR4-CCL17 axis can interfere with signaling pathways mediating Treg maintenance. (Weber, C. *et al.* (2011). J Clin Invest)
- CCR6 is a marker for migration to inflammatory sites. CCR6 and CCL20 are expressed at higher levels in human atherosclerotic plaques. (Calvayrac, O. *et al.* (2011). Arterioscler Thromb Vasc Biol)

**HIV+CVD+ individuals have particular signature of CD4 effector T-cells. Individuals in HIV+CVD+ group present highest levels of pro-atherogenic Th17 cells and Th2 cells.**



## Conclusions

These results reveal profound alterations in the frequency of regulatory and effector CD4+ T-cell subsets associated with atherosclerosis in ART-treated PLWH. The paucity and poor tissue-infiltration potential of anti-inflammatory CD39/CD73 Treg subsets may represent one mechanism contributing to atherosclerotic plaque formation during ART-treated HIV infection.

## Acknowledgments



the CTN  
CIHR Canadian  
HIV Trials Network

le Réseau  
Réseau canadien  
pour les essais VIH des IRS



Canadian HIV and  
Aging cohort (CTN 272)